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Purpose: Lens epithelial cell (LEC) apoptosis reduces the formation of posterior capsular opacification (PCO). The
involvement of caveolin-1 in the regulation of apoptosis has been previously demonstrated in epithelial cells. In this study,
we investigated the relationship between caveolin-1 and apoptosis of LECs under high glucose (HG) concentrations to
explore a mechanism in the formation of PCO in diabetic patients.
Methods: LECs were treated with high concentrations of glucose with or without epidermal growth factor (EGF) or
simvastatin in Dulbecco’s Modified Eagle’s Medium (DMEM). Induction of apoptosis was measured by flow cytometry,
and the expression of caveolin-1 was examined by immunofluorescence microscopy, quantitative real-time reverse
transcription polymerase chain reaction (RT–PCR), and immunoblotting.
Results: The expression of caveolin-1 was decreased, and the rate of apoptosis was increased in LECs treated with
increased glucose concentration and treatment duration. When simvastatin or EGF was added to HG-treated LECs,
caveolin-1 levels increased and the apoptosis rate of LECs decreased. Furthermore, colocalization of caveolin-1 and
phosphatidylserine (PS) on the cell surfaces of apoptotic LECs was observed by immunofluorescence microscopy.
Conclusions: We observed that in HG-treated LECs, caveolin-1 expression decreased and apoptosis increased and that
simvastatin or EGF promoted the proliferation of HG-treated LECs. Although the mechanisms for the formation of PCO
after cataract surgery in diabetic patients are complex, our results suggest that a high concentration of glucose is not a
direct cause. The observation that simvastatin inhibited the apoptosis of HG-treated LECs in its therapeutic concentration
suggests that daily dosage of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used by diabetic
patients may increase PCO formation.
Caveolin-1, a 21–24 kDa integral membrane protein, is
the  major  component  of  caveolae  that  are  flask-shaped
membrane  invaginations  involved  in  multiple  cellular
processes  such  as  vesicular  transport,  cholesterol
homeostasis, and most importantly, signal transduction [1,2].
Caveolin-1 plays a role in the organization and trafficking of
caveolae [3-5] and contains a scaffolding domain that enables
it to bind to several signaling proteins including epidermal
growth factor (EGF) receptors, sarcoma (Src)-family kinases,
protein kinases C (PKCs), endothelial nitric-oxide Synthase
(eNOS),  and  heterotrimeric  G-proteins  [4].  Binding  of
caveolin-1  to  these  signal  proteins  inhibits  their  activity.
However,  tyrosine  kinase-mediated  phosphorylation  of
caveolin-1  abolishes  this  inhibition  and  leads  to  cell
transformation and proliferation [6]. Caveolin-1 is present in
lens epithelial cells (LECs) [7-10] and plays a pivotal role in
many  cellular  processes  such  as  epithelial-mesenchymal
transdifferentiation  (EMT)  [11]  and  cell-to-cell
communications [12].
Posterior  capsular  opacification  (PCO)  reflects  the
wound-healing process of LECs in the capsular bag after
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cataract surgery and is caused by the proliferation and EMT
of LECs [13,14]. Recent data have shown that blocking the
growth of LECs after cataract extraction surgery by inducing
LEC  apoptosis  can  prevent  the  formation  of  PCO  [15].
Caveolin-1 has been shown to be involved in the regulation
of apoptosis in macrophages [16], fibroblasts, and epithelial
cells  [17,18].  In  the  present  study,  we  showed  that  high
glucose  (HG)  concentrations  in  culture  decreased  the
expression of caveolin-1 and caused LEC apoptosis while
EGF, which usually increases in aqueous humor after cataract
surgery,  and  simvastatin,  an  3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitor commonly used
in diabetic patients, enhanced the expression of caveolin-1 and
reduced apoptosis in HG-treated LECs. The results suggest
that the formation of PCO in diabetic patients after cataract
surgery may not be directly caused by high concentrations of
glucose but by other factors such as surgery.
METHODS
Materials: Human lens epithelial B3 (HLE-B3) cells were
obtained from ATCC (Rockville, MD). Dulbecco’s Modified
Eagle’s Medium (DMEM) and fetal bovine serum (FBS) were
obtained from Gibco (Grand Island, NY). Anti-caveolin-1
polyclonal  antibody  was  purchased  from  BD  Biosciences
Transduction  Laboratories  (San  Diego,  CA).  TRIZOL
reagent,  Vybrant®  apoptosis  assay  kit  #2,  and  rhodamine
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2008(TRITC)-conjugated  goat  anti-mouse  immunoglobulin  G
(IgG)  were  from  Invitrogen  Life  Technologies  (Carlsbad,
CA). Anti-mouse IgG horseradish peroxidase (HRP) antibody
was from Santa Cruz (Santa Cruz, CA). Polymerase chain
reaction (PCR) and RNA extraction kits were from Takara Co.
Ltd. (Ohtsu, Japan). EGF was from Sigma (St. Louis, MO).
Simvastatin  was  a  gift  from  Zhejiang  Medicine  Co.  Ltd.,
Xingchang Pharmaceutical Factory (Zhejiang, China). The
chemiluminescence (ECL) detection kit was from Amersham
Pharmacia (Arlington Heights, IL).
Cell  culture:  HLE-B3  cells  were  cultured  in  DMEM
supplemented with heat-inactivated (56 °C, 0.5 h) 10% FBS
at 37 °C in a humidified atmosphere with 5% CO2. To perform
experiments, the cells (70%–80% confluent) were seeded in
a 60-mm culture dish (Falcon; Becton-Dickinson, Oxnard,
CA), incubated with media containing 0.1% FBS (to prevent
slow apoptosis due to serum starvation) for 24 h, and then
treated  with  freshly  prepared  glucose  (5–25  mM),  a
combination of mannitol (20 mM) and glucose (5 mM; as a
control to exclude the effect of osmotic pressure), simvastatin
(10 nM), and EGF (0.1 ng/ml) in DMEM. At indicated time
points, the cells were collected for various assays.
Flow  cytometry  of  apoptosis:  Apoptosis  was  assessed  by
measuring membrane redistribution of phosphatidyl serine
(PS) using the Vybrant® apoptosis assay kit #2, which contains
propidium iodide (PI) and annexin V-conjugated Alexa Fluor
488 dye [19,20]. Cells were grown on a six-well plate at
1×106 cells per well and treated with glucose (5–25 mM) or
mannitol (20 mM) and glucose (5 mM) in DMEM for the
indicated time. To examine the effects of simvastatin or EGF
on apoptosis, cells were incubated with glucose (5 or 25 mM)
in DMEM containing simvastatin (10 nM) or EGF (0.1 ng/ml)
for 48 h. After the drug treatment, cells were collected, washed
twice with PBS, and resuspended in 500 μl binding buffer
containing annexin V antibody (5 μl) and PI (5 μl of 250 μg/
ml stock solution). After incubation on ice in the dark for 30
min, cells were evaluated with a fluorescence-activated cell
sorting (FACS) calibur flow cytometer (Becton Dickinson,
San Jose, CA). Basal apoptosis and necrosis were excluded,
and  the  percentage  of  cells  undergoing  apoptosis  was
determined  by  three  independent  experiments.  During  the
process, cell lysis rates were less than 0.5%.
Quantitative real-time RT–PCR of caveolin-1 mRNA: Total
RNA was isolated from HLE-B3 cells with TRIZOL reagent
according  to  the  manufacturer’s  protocol  and  used  as
templates to generate cDNA [21,22]. The caveolin-1 (CAV1)
mRNA  levels  were  quantified  by  real-time  reverse
transcription polymerase chain reaction (RT–PCR). Primers
were designed using the Primer Premier 5 software (Premier
Biosoft International, Palo Alto, CA) [23]. The following
primers  were  used  for  CAV1  and  β-actin  amplifications:
CAV1 (NM_001753) forward 5′-AAC GAT GAC GTG GTC
AAG ATT G-3′ and reverse 5′-TCC AAA TGC CGT CAA
AAC TGT −3′ (amplifying a 301 bp fragment) and β-actin
forward  5′-CAT  CAC  CAT  TGG  CAA  TGA  GC-3′  and
reverse 5′-TCG TCA TAC TCC TGC TTG C-3′ (amplifying
a  351  bp  fragment).  Primers  were  designed  to  include
sequences  from  the  extremes  of  two  exons  to  ensure  the
detection  of  the  corresponding  transcript,  avoiding
amplification of genomic DNA. Reactions were performed in
96-well plates with Optical-Quality eight-tube strips (Bio-Rad
Laboratories,  Hercules,  CA).  PCR  was  performed  using
SYBR Green I as the reporter dye. Increases in fluorescence
were measured real time during the extension step. The cDNA
was amplified under the following conditions: 95 °C for 10
min followed by 45 cycles for 15 s at 95 °C and 1 min at 59 °C.
The Ct value of each condition was the average of triplicate
runs.
Western blotting for caveolin-1: Proteins were extracted from
HLE-B3 cells as described previously [16], separated by 15%
SDS–PAGE,  and  transferred  to  polyvinylidene  fluoride
(PVDF) membranes. After blocking with Tris-buffered saline
containing Tween-20 (TBST; 20 mM Tris, 137 mM NaCl,
0.4%  Tween-20,  pH  7.6)  and  5%  non-fat  dried  milk,  the
membranes were incubated with primary antibodies in TBST
containing 1% non-fat dried milk at 4 °C for 16 h. Secondary
antibodies in TBST containing 1% non-fat dried milk were
then added for 2 h at room temperature. Bound secondary
antibodies  were  detected  using  an  enhanced
chemiluminescence  (ECL)  detection  system  (Amersham
Pharmacia  Biotech).  Changes  in  caveolin-1  protein  levels
were normalized to β-actin levels in each sample.
Immunofluorescence  microscopy  of  caveolin-1  and
phosphatidylserine: Cells were seeded on coverslips for 24 h.
After being treated with or without simvastatin (10 nM) or
EGF (0.1 ng/ml) in 25 mM glucose solution for 48 h, cells
were  fixed  with  paraformaldehyde  for  10  min  at  room
temperature and incubated with 0.1% Triton X-100 on ice for
5 min. To determine the colocalization of caveolin-1 and
phosphatidylserine (PS) in HLE-B3 cell membrane and to
analyze PS in apoptotic cells, cells treated with 25 mM glucose
for  48  h  were  incubated  with  5  μl  of  Alexa  Fluor  488-
conjugated annexin V in 100 μl of binding buffer (10 mM
HEPES, 140 mM NaCl, 2.5 mM CaCl, pH 7.4) for 15 min at
room temperature before being fixed with paraformaldehyde
for caveolin-1 staining. To visualize caveolin-1 in cells, the
coverslips were washed with PBS and sequentially incubated
at  room  temperature  in  PBS  containing  goat  serum,  anti-
caveolin-1  primary  antibody  at  1:200  dilution,  and
fluorescence-tagged secondary antibody for 1 h each. The
cells were then washed twice with PBS, mounted on glass
slides, and examined using a Leica fluorescence microscope
(Heidelberg, Germany).
Examination  of  caveolae  by  transmission  electron
microscopy : HLE-B3 cells were grown on a six-well plate at
1×106 cells per well and treated as described above. Cells were
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2009then  fixed  with  glutaraldehyde,  post-fixed  with  osmium
tetroxide, stained with uranyl acetate and lead citrate, and
examined  using  a  Philips  410  transmissions  electron
microscope  (TEM;  Eindhoven,  Netherlands)  as  described
previously [24,25].
Statistical  analysis:  The  results  are  presented  as  mean
±standard  error  (SE).  Differences  between  groups  were
assessed by one-way analysis of variance (ANOVA) followed
by post-hoc test with the S-N-K method. Calculations were
performed using SPSS for Windows version 13.0 statistical
package (SPSS, Chicago, IL). p values less than 0.05 were
considered statistically significant.
RESULTS
Effects  of  high  glucose  concentrations  on  apoptosis  and
caveolin-1 expression in HLE-B3 cells: Based on previous
reports  [26,27],  we  cultured  HLE-B3  cells  with  various
concentrations (5–25 mM) of glucose for various lengths of
time (1–48 h) to evaluate dose and time responses of cells to
glucose. As described previously, 5 mM glucose represents
the normal physiologic level and 25 mM the high level [26,
27]. As shown in Figure 1A, 4.13%±0.74%, 9.12%±1.19%,
11.42%±1.68%,  16.00%±2.47%,  and  18.53%±1.01%
increases in the apoptosis rate were observed in cells treated
with 5, 10, 15, 20, and 25 mM glucose for 48 h, respectively.
A  significant  decrease  in  CAV1  mRNA  levels  was  also
observed in cells treated with 5–25 mM of glucose (Figure
2A). Cells treated with 25 mM glucose had the lowest CAV1
mRNA levels. In agreement with the RT–PCR data, decreased
levels of caveolin-1 protein were detected in cells treated with
10–25 mM glucose for 48 h compared to the control (Figure
3A). After being incubated with 25 mM glucose from 1 h to
48  h,  an  increase  in  apoptosis  was  observed  from  4.01%
±0.08% at 1 h to 14.03%±0.52% at 24 h, reaching a maximum
of 18.53%±1.01% at 48 h (Figure 1B). However, it was found
that longer treatment time resulted in a lower level of CAV1
expression (Figure 2B). The protein levels of caveolin-1 were
also decreased in cells treated with 25 mM glucose for 12–48
h (Figure 3B). Based on these results, we selected 25 mM as
the high glucose concentration and 48 h as the treatment time
for subsequent studies.
Cells treated with HG (25 mM) for 48 h exhibited a
significantly  higher  apoptosis  rate  and  less  caveolin-1
expression  than  those  of  the  control  (treated  with  5  mM
Figure 1. Effects of high concentrations
of  glucose  on  apoptosis  of  HLE-B3
cells. Cells were incubated with 5–25
mM glucose for 48 h (A) or with 25 mM
glucose  for  1–48  h  (B).  Cells  treated
with 5 mM glucose and 20 mM mannitol
were  used  as  an  osmotic  control.
Apoptosis was determined by using the
Vybrantan® apoptosis assay kit #2 and
by flow cytometry. Experiments were
performed  in  triplicate.  The  asterisk
indicates p<0.05 versus control, and the
hash  mark  denotes  p>0.05  versus
control
Figure  2.  Caveolin-1  (CAV1)  mRNA
levels in HLE-B3 cells treated with high
concentrations  of  glucose.  Cells  were
treated  with  the  indicated
concentrations of glucose in DMEM for
48 h (A) or with 5 mM (control) or 25
mM glucose in DMEM for 1–48 h (B).
CAV1 mRNA levels were determined
by real-time RT–PCR and normalized to
those of β-actin. Cells treated with 5 mM
glucose and 20 mM mannitol were used
as an osmotic control. The experiments
were  performed  in  triplicate.  A:  The
asterisk indicates p<0.01 versus control,
and  the  hash  mark  denotes  p>0.05
versus control. B: The asterisk indicates
p<0.05,  and  the  hash  mark  denotes
p>0.05.
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2010glucose). Furthermore, the addition of mannitol as an osmotic
control did not influence the apoptosis rate or the expression
of caveolin-1. These results indicate that apoptosis in HLE-
B3 cells after HG exposure was associated with decreased
expression of caveolin-1.
Effects of HG on subcellular localization of caveolin-1 and
phosphatidylserine in HLE-B3 cells: To examine whether the
change in caveolin-1 protein expression is related to HG-
induced apoptosis, we immunostained the control and HG-
treated cells for caveolin-1 and PS (Figure 4). Caveolin-1
fluorescence  intensity  was  relatively  high  in  control  cells
(Figure 4A) but was greatly reduced in cells treated with
25  mM  glucose  (Figure  4B),  indicating  a  decrease  in
caveolin-1 levels in HG-treated HLE-B3 cells. A significant
increase  in  the  number  of  double-stained  cells  was  also
observed  in  HG-treated  HLE-B3  cells  (Figure  4C,D).  As
caveolin-1 and PS were both present on the cell surface, the
decrease  in  caveolin-1  expression  and  the  increase  in  PS
externalization suggested a role of caveolin-1 in the apoptotic
process. Therefore, we further examined whether caveolin-1
distribution in apoptotic cells resembled that of PS on the cell
surface  by  staining  HG-treated  HLE-B3  cells  for  both
caveolin-1 and PS. After being treated with 25 mM glucose
for 48 h, PS was found to be translocated from the inner
plasma membrane to the outer membrane and was associated
with caveolin-1 (Figure 4E,F,G). Since caveolin-1 is the major
component of caveolae, a decrease in caveolin-1 may reduce
caveolae formation. To further characterize the changes of
caveolin-1 in HG-treated HLE-B3 cells, the distribution of
caveolae  in  cells  was  analyzed  by  transmission  electron
microscopy  (Figure  5A,B).  As  expected,  the  number  of
caveolae was greatly reduced in cells treated with 25 mM
glucose (Figure 5B).
Effect of increased caveolin-1 expression on apoptosis of HG-
induced  HLE-B3  cells:  Previous  studies  have  shown  that
caveolin-1 in conjunction with HMG-CoA reductase plays an
important role in cellular cholesterol homeostasis [16,28,29].
In addition, the CAV1 mRNA levels can be regulated under
conditions where the cellular cholesterol level is altered [30].
To investigate the effect of HMG-CoA reductase inhibition
by simvastatin on caveolin-1 expression, HLE-B3 cells in
culture  media  containing  5  mM  or  25  mM  glucose  were
incubated  for  48  h  with  10  nM  of  simvastatin,  which
represents the clinical therapeutic concentration in diabetic
patients  [31,32].  Results  of  real-time  RT–PCR  and  flow
cytometry showed no significant changes in CAV1 mRNA
levels and apoptosis in cells treated with 5 mM glucose and
with or without simvastatin stress (Figure 6A,B). However,
the CAV1 mRNA levels in HLE-B3 cells treated with 25 mM
glucose and 10 nM simvastin increased (Figure 6A), and the
percentages of apoptotic cells decreased from 18.53%±1.01%
to 5.52%±1.22% when compared to the control (Figure 6B).
EGF has been shown to activate the phosphorylation of
caveolin-1 [6] and influence caveolae assembly on the cell
surface [33]. To examine the effect of EGF on caveolin-1
expression, we treated HLE-B3 cells with 5 or 25 mM glucose
and 0.1 ng/ml EGF [34] for 48 h. Compared to the HG-treated
control, treatment with 25 mM glucose and 0.1 ng/ml EGF
significantly increased CAV1 mRNA levels and decreased
apoptosis by 3.21%±0.87% (Figure 7A,B). Similarly, western
blot analysis showed that HG incubation reduced caveolin-1
protein levels (Figure 8). The addition of 0.1 ng/ml EGF or 10
nM  simvastatin  in  25  mM  glucose  notably  increased
caveolin-1 protein levels (Figure 8) compared to control cells
that were treated only with 25 mM glucose. These results
indicate  that  increased  CAV1  expression  due  to  EGF  or
simvastatin stimulation was related to the inhibition of HLE-
B3 cell apoptosis under high concentrations of glucose.
DISCUSSION
Caveolae,  the  sphingomy-cholesterol  enriched
microdomains, form a stable lipid matrix that act as an ordered
support for receptor-mediated signaling events. It has been
proposed that caveola composition changes in response to
adverse extracellular conditions [35,36]. Consistent with this
hypothesis, we found in the current study that HG treatment
led to a decrease in the number of caveolae on the surface of
LECs. We also found reduced levels of caveolin-1 mRNA and
protein  in  HG-treated  LECs,  indicating  that  caveolin-1
expression was down-regulated at the transcription level.
Although it has been proposed that caveolin-1 functions
as a message center that compartmentalizes anti- and pro-
apoptotic signaling molecules on the cell surface to regulate
apoptosis  [17],  its  role  in  regulating  apoptosis  remains
controversial. In the current study, we found the levels of
caveolin-1 reduced and apoptosis rate increased in HG-treated
Figure  3.  Western  blot  analysis  of
caveolin-1 in HLE-B3 cells treated with
high  concentrations  of  glucose.  Cells
were  treated  with  the  indicated
concentrations of glucose in DMEM for
48 h (A) or 25 mM glucose in DMEM
for 1–48 h (B). Cells treated with 5 mM
glucose and 20 mM mannitol were used
as an osmotic control. The experiments
were performed in triplicate.
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2011Figure 4. Subcellular distribution of caveolin-1 and externalization of phosphatidylserine in HLE-B3 cells treated with high concentrations
of glucose. HLE-B3 cells were treated with 5 mM glucose (A, C) or 25 mM glucose (B, D, E, F) for 48 h and then reacted with anti-caveolin-1
polyclonal  primary  antibody  (1:200;  A,  B,  E)  or  Alexa  Fluor  488-conjugated  annexin  V  (C,  D,  F).  Cells  were  examined  with  an
immunofluorescent microscope. G is a merged image of E and F, indicating colocalization of caveolin-1 and PS in the cell membrane. The
scale bars indicate 15 μm.
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2012LECs,  indicating  that  caveolin-1  may  inhibit  apoptosis.
However,  overexpression  of  caveolin-1  in  fibroblasts  and
epithelial cells has been shown to sensitize these cells to
staurosporine-induced apoptosis, possibly via inhibition of
phosphoinositide  3-kinase  (PI3K)  and/or  activation  of
caspase-3  [17,18].  The  hypercellularity  of  the  lung
parenchyma  and  the  increased  proliferative  phenotype  of
mouse embryo fibroblasts from caveolin-1 knockout mice are
consistent with the anti-proliferative properties of caveolin-1
[37,38].  In  contrast,  Timme  et  al.  [39]  showed  that
overexpression of caveolin-1 maintained Akt in an active state
in  prostate  cancer  cells  by  inhibiting  protein  phosphatase
activity,  a  mechanism  that  may  contribute  to  cellular
resistance  to  c-myc-induced  apoptosis.  This  discrepancy
suggests that the involvement of caveolin-1 in the regulation
of proliferation or apoptosis may not be cell-specific but rather
dependent on cellular events.
In HG-treated LECs, simvastatin was found to cause an
increase in the expression of caveolin-1 and inhibition of LEC
apoptosis. Similarly, it has been reported that simvastatin
upregulates caveolin-1 expression in human smooth muscle
cells [40] and macrophages [15] and normalizes the vascular
cell  phenotype  in  severe  pulmonary  hypertension  [41].
However, Lecian et al. [29] found that simvastatin decreases
caveolin-1 expression in Madin-Darby canine kidney cells.
Recent  reports  have  demonstrated  that  caveolin-1  binds
cholesterol, and cholesterol is thought to intercalate under the
sphingolipid head groups, thus facilitating tighter packing and
decreasing  entropy  [42].  The  agents  that  can  change
cholesterol concentrations within caveolae have been shown
to regulate caveolin-1 expression and alter cellular signaling
[43,44]. We, therefore, speculated that the contribution of
simvastatin in the regulation of caveolin-1 expression may be
cell-specific and related to simvastatin effects beyond lipid
lowering [45].
Figure 5. Transmission electron microscopy of caveolae in HLE-B3 cells treated with high concentrations of glucose. Cells were seeded on
glass coverslips, treated with 5 mM or 25 mM glucose for 48 h, fixed with glutaraldehyde, post-fixed with osmium tetroxide, and stained with
uranyl acetate and lead citrate. A: 5 mM glucose-treated (control) cells. Arrows point to caveolae. B: 25 mM glucose-treated cells.
Figure  6.  Effects  of  simvastatin  on
caveolin-1 expression and apoptosis in
HLE-B3  cells  treated  with  high
concentrations  of  glucose.  Cells  were
treated with simvastatin (10 nM) and
glucose (5 or 25 mM) for 48 h. The ∆Ct
values of CAV1 mRNA levels (A) and
the percentages of apoptotic cells (B)
were determined by real-time RT–PCR
and  flow  cytometry,  respectively.
Experiments  were  performed  in
triplicate.  A:  The  asterisk  indicates
p<0.01,  and  the  hash  mark  denotes
p>0.05.  B:  The  asterisk  indicates
p<0.05,  and  the  hash  mark  denotes
p>0.05.
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2013EGF was also found to increase caveolin-1 expression
and inhibit apoptosis in HG-treated LECs. A large body of
evidence has shown that caveolin-1 interacts with epidermal
growth factor receptor (EGFR). Tencer et al. [46] reported that
upregulation  of  caveolin-1  by  EGF  activates  EGFR.  In
addition, overexpression of caveolin-1 in the MCF-7 breast
cancer cell line has been shown to modulate EGFR activation
levels and EGF-induced EGFR signaling [47]. It has also been
shown that EGF regulation contributes to the stability of CAV1
mRNA [48,49]. Since HT-29 human colon cancer cells are
not sensitive to EGF stimulation due to the lack of a canonical
peroxisome proliferator-activated receptor-gamma response
element (PPRE) [46], we speculated that EGF may regulate
caveolin-1  expression  through  peroxisome  proliferator-
activated receptor-gamma.
We also found that caveolin-1 was present on the surface
of HG-treated LECs and colocalized with PS in the outer
membrane of apoptotic LECs. Our results suggest that PS
externalization is related to the presence of caveolin-1 in the
cell membrane and the regulatory elements involved in PS
externalization  in  apoptotic  LECs  under  HG  conditions.
Previous  reports  indicate  that  store-operated  Ca2+  entry
regulates externalization of PS on the cell surface and that PS
exposure  is  dependent  in  part  on  the  extracellular  signal-
regulated kinase pathway associated with caveolin-1 [50].
Further investigations to corroborate the relationship between
caveolin-1 and store-operated Ca2+ entry in HG-treated LECs
are required.
Uncontrolled  diabetes  mellitus  (DM)  may  lead  to
systemic  and  ocular  complications  including  cataracts
[51-54]. Although cataract surgery has been greatly improved
due  to  the  development  of  phacoemulsification,  posterior
capsular  opacification  remains  the  major  complication  in
diabetic  patients  [55-57].  However,  the  finding  that  LEC
apoptosis has effects on PCO in diabetic patients after cataract
surgery is still controversial. Zaczek et al. [57] found less PCO
Figure 7. Effects of EGF on caveolin-1
expression  and  apoptosis  in  HLE-B3
cells treated with high concentrations of
glucose.  Cells  were  incubated  in
DMEM  containing  both  glucose  and
EGF at the indicated concentrations for
48 h. The ∆Ct values of CAV1 mRNA
levels  (A)  and  the  percentages  of
apoptotic cells (B) were determined by
real-time RT–PCR and flow cytometry,
respectively.  Experiments  were
performed in triplicate. A: The asterisk
indicates  p<0.01,  and  the  hash  mark
denotes  p>0.05.  B:  The  asterisk
indicates  p<0.05,  and  the  hash  mark
denotes p>0.05.
Figure  8.  Effects  of  simvastatin  and
EGF on the levels of caveolin-1 protein
in  HLE-B3  cells  treated  with  high
concentrations  of  glucose.  Cells  were
incubated with 5 mM or 25 mM glucose
in the presence or absence of either 10
nM simvastatin or 0.1 ng/ml EGF for 48
h. The levels of caveolin-1 protein were
analyzed  by  western  blot.  The
experiments  were  performed  in
triplicate. HG: 25 mM glucose; Control:
5 mM glucose.
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2014occurrence in diabetic patients than in non-diabetic patients
after phacoemulsification surgery and speculated that damage
to  LECs  and  the  decreased  proliferative  activity  of  the
damaged LECs may reduce PCO in diabetic patients under
hyperglycemic  conditions.  However,  Hayashi  et  al.  [58]
reported greater PCO occurrence in diabetic patients than in
non-diabetic patients and suggested that the disruption of the
blood-aqueous  barrier  and  inflammatory  reaction  after
cataract surgery is more severe in the eyes of diabetic patients.
Since  the  mechanism  regulating  the  proliferation  and
epithelial-mesenchymal transdifferentiation of LECs is not
completely understood, the reason for the discrepant findings
in PCO formation between diabetic and non-diabetic patients
remains unclear.
In the current study, we observed that high concentrations
of glucose inhibited LEC proliferation in culture and that
simvastatin and EGF promoted LEC growth. We, therefore,
speculate that high concentrations of glucose may not be a
direct cause for the formation of PCO in diabetic patients. The
higher incidence of PCO after cataract surgery in diabetic
patients could be due to escalated chemical mediators such as
interleukin-1 (IL-1), IL-6, IL-8, and EGF resulting from the
breakdown of the blood-aqueous barrier after surgery. These
chemical mediators may lead to an increased proliferation of
LECs [59]. Our observation that simvastatin inhibited LEC
apoptosis  in  its  therapeutic  concentration  suggests  daily
dosage of HMG-CoA reductase inhibitor used by diabetic
patients may increase PCO formation.
In summary, we found that high concentration of glucose
decreased caveolin-1 expression and increased the apoptosis
rate of LECs and that simvastatin and EGF promoted the
proliferation of LECs under a high concentration of glucose.
Although the mechanisms for the formation of PCO after
cataract surgery in diabetic patients are complex, our results
suggest that high concentration of glucose is not a direct cause.
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